KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
KAUST startup uODS signed an MoU with Saudi Aramco Base Oil Company (Luberef) to develop and deploy technology removing sulfur from hydrocarbons. The uODS process, based on KAUST's sonochemistry research, reduces sulfur in marine fuels to meet IMO 2020 regulations. Luberef aims to reduce its environmental footprint by piloting the uODS technology at its Jeddah refineries, with uODS set to produce 10 tons per day of desulfurized fuel for testing. Why it matters: The partnership demonstrates KAUST's role in addressing Saudi Arabia's environmental goals and showcases the potential of university spin-offs to contribute to a more sustainable oil industry in the region.
KAUST startup Lihytech has raised US$6 million in funding from Ma'aden and the KAUST Innovation Ventures Fund. Lihytech's patented membrane technology, developed by Professor Zhiping Lai at KAUST, extracts battery-grade lithium from sources like seawater. The funding will be used to build a pilot facility at KAUST to extract lithium from the Red Sea and other in-Kingdom resources. Why it matters: This investment supports Saudi Arabia's goal of developing a complete electric vehicle value chain and becoming a key player in meeting global lithium demand.
Researchers at KAUST and Peking University Third Hospital have created a novel blastoid model for studying early human development using extended pluripotent stem cells (EPSCs). The blastoid is a 3D cell model mimicking the blastocyst phase, avoiding ethical concerns associated with using human embryos. The team showed that blastoids can be cultured to mimic post-implantation development, offering insights into early cell lineages. Why it matters: This innovation provides a way to study human embryogenesis without the ethical constraints of using actual embryos, potentially advancing our understanding of miscarriage and birth defects.